NCT06022588

Brief Summary

Background and aims: A gold standard diagnostic test to diagnose chronic mesenteric ischemia is currently lacking. Isotope labelled-butyrate and glucose breath testing could theoretically quantify mucosal oxygen consumption and thereby detect ischemia, since oxygen is needed to absorb and metabolize butyrate and glucose, and distinguish aerobic/anaerobic intestinal epithelial metabolism. Here we aim to test this notion and compare results to conventional biomarkers. Methods: Healthy volunteers were randomized into two control groups and two intervention groups, each consisting of five volunteers receiving either oral 13C -butyrate or 13C -glucose. The control groups performed breath tests without any physical exercise. The intervention groups performed a 30 minutes standardized bicycle exercise test, which has been proven to elicit mesenteric ischemia. Breath samples of expired 13CO2 were collected during a period of 4 hours and results were contrasted to measurements of biomarkers in peripheral blood.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2021

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2021

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2021

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

July 26, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

September 5, 2023

Completed
Last Updated

September 5, 2023

Status Verified

August 1, 2023

Enrollment Period

1 month

First QC Date

July 26, 2023

Last Update Submit

August 30, 2023

Conditions

Keywords

Chronic mesenteric ischemiaDiagnosticBreath test

Outcome Measures

Primary Outcomes (1)

  • The median concentrations of measured 13CO2

    The median concentrations of measured 13CO2 at each time point where compared within the four groups and statistically tested with a Mann - Whitney U test.

    At the following time points; baseline, 0.5, 1, 1.25 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5 and 4 hours (total of 12 time points) after ingestion of 13C-butyrate or 13C-glucose.

Study Arms (4)

13C -butyrate control group

PLACEBO COMPARATOR

5 healthy volunteers performed the breath test without any psychical exercise

Drug: Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USADiagnostic Test: Breath test

13C -butyrate intervention group

EXPERIMENTAL

5 healthy volunteers performed the breath test with psychical exercise - bicycle test

Drug: Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USADiagnostic Test: Exercise + breath test

13C -glucose control group

PLACEBO COMPARATOR

5 healthy volunteers performed the breath test without any psychical exercise

Drug: U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USADiagnostic Test: Exercise + breath test

13C -glucose intervention group

EXPERIMENTAL

5 healthy volunteers performed the breath test with psychical exercise - bicycle test

Drug: U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USADiagnostic Test: Exercise + breath test

Interventions

a solution containing butyrate of which 12C of the last 4 carbon positions of butyrate were replaced by 13C butyrate. Participants received 0.80 gram 13C-butyrate (7.3 mMol butyrate / 29 mMol 13C) dissolved in 50 mL water at baseline

Also known as: 13C butyrate
13C -butyrate control group13C -butyrate intervention group

a glucose solution in which all six 12C carbons were replaced by 13C D-Glucose. Participants received 0.75 gram 13C-glucose (4.2 mMol D-glucose/ 25 mMol 13C) dissolved in 50 mL water at baseline

Also known as: 13C glucose
13C -glucose control group13C -glucose intervention group
Breath testDIAGNOSTIC_TEST

Breath tests were performed at the following time points baseline, 0.5, 1, 1.25 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5 and 4 hours after ingestion of 13C-butyrate and 13C-glucose. Breath samples were obtained by blowing a single breath of air through a straw into a test tube. Two breath samples were collected at all mentioned time points. Measurement of 13CO2 is performed using mass spectrometry (IDMicro Breath, Compact Science Systems, Newcastle-Under-Lyme, United Kingdom) using procedures described earlier for galactose and methacetin breath tests, and expressed as an absolute increase in the 13CO2-to-12CO2 ratio in delta permil (δ‰).

13C -butyrate control group
Exercise + breath testDIAGNOSTIC_TEST

The intervention groups performed a standardized bicycle ergometer exercise test of 30 minutes and semi-continuous peripheral blood lactate monitoring. The bicycle ergometer protocol consists of three phases. The first 10 minutes of exercise was used to gradually increase the workload until submaximal exercise intensity was reached which is defined as a circulating blood lactate level between 3 and 5.5 mmol/L. From minute 10 to 20 submaximal exercise intensity was maintained by adjusting the workload based on lactate measurements. Minute 20 to 30 was used to reach maximal exercise intensity, the workload was increased by 10% of the submaximal workload until exhaustion

13C -butyrate intervention group13C -glucose control group13C -glucose intervention group

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • healthy volunteers without any gastrointestinal complaints

You may not qualify if:

  • pregnant woman

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Erasmus Medical Center - Department of Gastroenterology

Rotterdam, Netherlands

Location

MeSH Terms

Conditions

Disease

Interventions

Butyric AcidBreath TestsExercise

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

ButyratesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsFatty Acids, VolatileFatty AcidsLipidsDiagnostic Techniques and ProceduresDiagnosisMotor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Marco Bruno, prof.

    Erasmus Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Gastroenterologist

Study Record Dates

First Submitted

July 26, 2023

First Posted

September 5, 2023

Study Start

March 1, 2021

Primary Completion

April 1, 2021

Study Completion

August 1, 2021

Last Updated

September 5, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will not share

Locations